Skip to content

Effect of Transcutaneous Electroacupuncture on Functional Abdominal Bloating/Distension

Effect of Transcutaneous Electroacupuncture on Patients With Functional Abdominal Bloating/Distension

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04916106
Enrollment
60
Registered
2021-06-07
Start date
2020-01-01
Completion date
2022-01-31
Last updated
2021-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Abdominal Bloating/Distension

Keywords

Functional Bloating/Distension, Transcutaneous electrical acupoint stimulation

Brief summary

Functional abdominal bloating/distension (FAB/D) is a common functional bowel disorder that lacks effective treatment options. Transcutaneous electroacupuncture (TEA) as a new therapeutic method has great effect on functional gastrointestinal diseases such as functional dyspepsia and functional constipation. Research on TEA for FAB/D has not yet been explored.

Detailed description

Functional abdominal bloating/distension (FAB/D) is a common functional bowel disorder that lacks effective treatment options. Rome IV was introduced in 2016. Studies have shown that bloating may affect about 30% general population and 96% of patients with functional gastrointestinal disorders (FGID).Transcutaneous electroacupuncture (TEA) as a new therapeutic method has great effect on functional gastrointestinal diseases such as functional dyspepsia and functional constipation. Research on TEA for FAB/D has not yet been explored. Thirty patients who fulfilled the Rome IV diagnostic criteria of FAB/D in the department of the second affiliated hospital of Xi'an jiaotong University.Inclusion criteria included: Symptoms of recurrent abdominal fullness, pressure, or a sensation of trapped gas (bloating), and/or measurable (objective) increase in abdominal girth (distention) more than 6 month;the main symptoms appeared in the past 3 months;Not taking related drugs; aged 18-65 years old;From January 2020 to December 2021; Sign informed consent. All patients were randomly assigned to 3 groups and received TEA at Zusanli (ST36) and Neiguan (PC6) with 3 diffrent parameter for 4weeks. The symptom severity score, abdominal girth, electrogastrogram (ECG) and orocecal transit time (OCTT) ,heart rate variability (HRV) ,rectal sensitivity and intestinal flora were recorded at baseline and after 2-week treatment, respectively. The symptom severity score was repeated at baseline and after 4-week treatment. Through the comparison of the index before and after TEA treatment to identify optimal stimulation parameters and explore its possible mechanism. The study was proved by the medical ethics committee of the Second Affiliated Hospital of Xi'an jiaotong University.

Interventions

give diffrent parameter TEA treatment for 4 weeks.

Sponsors

Second Affiliated Hospital of Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Clinical diagnosis of Functional bloating/distension with Rome IV; 2. Aged 18-65 years old;

Exclusion criteria

1. Have taken drugs that may affect gastrointestinal motility in the past week; 2. Have taken antibiotics and probiotics in the past month; 3. The history of gastrointestinal surgery; 4. Helicobacter pylori is not cleared; 5. Pregnant and breastfeeding women; 6. Skin allergies.

Design outcomes

Primary

MeasureTime frameDescription
Orocecal ransit timeafter 1-month TEA treatmentthe lactulose hydrogen breath test was used to evaluate the intestinal transit time and observe the presence or absence of excessive small intestinal bacteria
Heart rate variability(HRV)after 1-month TEA treatmentAssessment of autonomic function with heart rate variability
Flora structureafter 1-month TEA treatmentan Illumina MiSeq Platform was used to sequence 16S ribosomal RNA (rRNA) gene of the total bacteria in fecal samples.
Rectal sensitivityafter 1-month TEA treatmentRectal threshold for gas and defecation
Plasma gastrointestinal peptide levelafter 1-month TEA treatmentCCK、SP、NPY、CGRP、Motilin
Symptom improvement rateafter 1 month TEA treatmentthe symptom severity score with VAS and abdominal girth measurements
The percentage of the normal gastric slow waves in electrogastrographafter 1 month TEA treatmentThe percentage of the normal gastric slow waves in fasting 、fed states and the post-preprandial EGG power ratio

Countries

China

Contacts

Primary ContactFei Dai
daifei68@hotmail.com13772151298
Backup ContactYindi Chen
daifei68@hotmail.com18119487105

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026